EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency

Wenyu Zhang, Jingmei Li, Keita Yamamoto, Susumu Goyama

International Journal of Hematology · 2024

DOI: 10.1007/s12185-024-03783-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Wenyu Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tok…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Tumor Suppressor Protein p53, Chromosomes, Human, Pair 8, Translocation, Genetic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grant-in-Aid for Scientific Research (B), Grant-in-Aid for Scientific Research on Innovative Areas, JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) with t(8;21)(q22;q22.1);RUNX1-ETO is one of the most common subtypes of AML. Although t(8;21) AML has been classified as favorable-risk, only about half of patients are cured with current therapies. Several genetic abnormalities, including TP53 mutations and deletions, negatively impact survival in t(8;21) AML. In this study, we established Cas9 + mouse models of t(8;21) AML with intact or deficient Tpr53 (a mouse homolog of TP53 ) using a retrovirus-mediated gene transfer and transplantation system. Trp53 deficiency accelerates the in vivo development of AML driven by RUNX1-ETO9a, a short isoform of RUNX1-ETO with strong leukemogenic potential. Trp53 deficiency also confers resistance to genetic depletion of RUNX1 and a TP53-activating drug in t(8;21) AML. However, Trp53 -deficient t(8;21) AML cells were still sensitive to several drugs such as dexamethasone. Cas9 + RUNX1-ETO9a cells with/without Trp53 deficiency can produce AML in vivo, can be cultured in vitro for several weeks, and allow efficient gene depletion using the CRISPR/Cas9 system, providing useful tools to advance our understanding of t(8;21) AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteTumor Suppressor Protein p53Chromosomes, Human, Pair 8Translocation, GeneticChromosomes, Human, Pair 21Disease Models, AnimalCore Binding Factor Alpha 2 SubunitAnimalsMiceHumansOncogene Proteins, Fusion

Stichwörter der Autor:innen

AMLCRISPR/Cas9Mouse modelRUNX1-ETOTP53

Substanzen

Tumor Suppressor Protein p53Core Binding Factor Alpha 2 SubunitTrp53 protein, mouseOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
  • Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. goyama@edu.…

Förderung

  • Grant-in-Aid for Scientific Research (B)
  • Grant-in-Aid for Scientific Research on Innovative Areas
  • JSPS KAKENHI
  • AMED
  • The University of Tokyo

Zitieren

APA

Zhang, W., Li, J., Yamamoto, K., & Goyama, S. (2024). Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03783-3

Vancouver

Zhang W, Li J, Yamamoto K, Goyama S. Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03783-3

BibTeX
@article{Zhang2024,
  author = {Zhang, Wenyu and Li, Jingmei and Yamamoto, Keita and Goyama, Susumu},
  title = {Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency},
  journal = {International Journal of Hematology},
  year = {2024},
  doi = {10.1007/s12185-024-03783-3}
}
Kostenlos starten →